Literature DB >> 17293497

Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury.

Christopher K Means1, Chun-Yang Xiao, Zhuangjie Li, Tong Zhang, Jeffrey H Omens, Isao Ishii, Jerold Chun, Joan Heller Brown.   

Abstract

Sphingosine 1-phosphate (S1P) is released at sites of tissue injury and effects cellular responses through activation of G protein-coupled receptors. The role of S1P in regulating cardiomyocyte survival following in vivo myocardial ischemia-reperfusion (I/R) injury was examined by using mice in which specific S1P receptor subtypes were deleted. Mice lacking either S1P(2) or S1P(3) receptors and subjected to 1-h coronary occlusion followed by 2 h of reperfusion developed infarcts equivalent to those of wild-type (WT) mice. However, in S1P(2,3) receptor double-knockout mice, infarct size following I/R was increased by >50%. I/R leads to activation of ERK, JNK, and p38 MAP kinases; however, these responses were not diminished in S1P(2,3) receptor knockout compared with WT mice. In contrast, activation of Akt in response to I/R was markedly attenuated in S1P(2,3) receptor knockout mouse hearts. Neither S1P(2) nor S1P(3) receptor deletion alone impaired I/R-induced Akt activation, which suggests redundant signaling through these receptors and is consistent with the finding that deletion of either receptor alone did not increase I/R injury. The involvement of cardiomyocytes in S1P(2) and S1P(3) receptor mediated activation of Akt was tested by using cells from WT and S1P receptor knockout hearts. Akt was activated by S1P, and this was modestly diminished in cardiomyocytes from S1P(2) or S1P(3) receptor knockout mice and completely abolished in the S1P(2,3) receptor double-knockout myocytes. Our data demonstrate that activation of S1P(2) and S1P(3) receptors plays a significant role in protecting cardiomyocytes from I/R damage in vivo and implicate the release of S1P and receptor-mediated Akt activation in this process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293497     DOI: 10.1152/ajpheart.01331.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  101 in total

1.  An entirely specific type I A-kinase anchoring protein that can sequester two molecules of protein kinase A at mitochondria.

Authors:  Christopher K Means; Birgitte Lygren; Lorene K Langeberg; Ankur Jain; Rose E Dixon; Amanda L Vega; Matthew G Gold; Susanna Petrosyan; Susan S Taylor; Anne N Murphy; Taekjip Ha; Luis F Santana; Kjetil Tasken; John D Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

Review 2.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  Extracellular and intracellular sphingosine-1-phosphate distinctly regulates exocytosis in chromaffin cells.

Authors:  Zhong-Jiao Jiang; Taylor L Delaney; Mark P Zanin; Rainer V Haberberger; Stuart M Pitson; Jian Huang; Simon Alford; Stephanie M Cologna; Damien J Keating; Liang-Wei Gong
Journal:  J Neurochem       Date:  2019-05-08       Impact factor: 5.372

Review 5.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

Review 6.  Lysophospholipids in coronary artery and chronic ischemic heart disease.

Authors:  Ahmed Abdel-Latif; Paula M Heron; Andrew J Morris; Susan S Smyth
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

7.  Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction.

Authors:  Che-Chung Yeh; Hongzhe Li; Deepak Malhotra; Mei-Chuan Huang; Bo-Qing Zhu; Edward J Goetzl; Donald A Vessey; Joel S Karliner; Michael J Mann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-20       Impact factor: 4.733

8.  Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2.

Authors:  Hitoshi Ikeda; Naoko Watanabe; Isao Ishii; Tatsuo Shimosawa; Yukio Kume; Tomoaki Tomiya; Yukiko Inoue; Takako Nishikawa; Natsuko Ohtomo; Yasushi Tanoue; Satoko Iitsuka; Ryoto Fujita; Masao Omata; Jerold Chun; Yutaka Yatomi
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

9.  Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice.

Authors:  Tong Zhang; Tao Guo; Shikha Mishra; Nancy D Dalton; Evangelia G Kranias; Kirk L Peterson; Donald M Bers; Joan Heller Brown
Journal:  Circ Res       Date:  2009-12-03       Impact factor: 17.367

10.  Focal adhesion kinase as a RhoA-activable signaling scaffold mediating Akt activation and cardiomyocyte protection.

Authors:  Dominic P Del Re; Shigeki Miyamoto; Joan Heller Brown
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.